Itkin, T
Kumari, A
Schneider, E
Gur-Cohen, S
Ludwig, C
Brooks, R
Kollet, O
Golan, K
Khatib-Massalha, E
Russo, C M
Chisholm, J D
Rouhi, A
Geiger, H
Hornstein, E
Kerr, W G
Kuchenbauer, F
Lapidot, T
Article History
First Online: 8 February 2017
Competing interests
: WGK has an equity position in a private venture that may license and commercialize SHIP-1 inhibitor technology for mobilization and harvest of BM stem cells. The remaining authors declare no conflict of interest.